Welcome to our dedicated page for Psychemedics news (Ticker: PMD), a resource for investors and traders seeking the latest updates and insights on Psychemedics stock.
Psychemedics Corp (PMD) delivers cutting-edge hair analysis solutions for substance abuse detection, serving corporations and government agencies worldwide. This news hub provides investors and professionals with essential updates on the company's operational milestones and industry leadership.
Access consolidated reports on quarterly earnings, scientific advancements, and regulatory developments shaping the drug testing sector. Our repository includes press releases about new service launches like ketamine detection, strategic partnerships, and innovations such as Quartile Reporting technology.
This resource enables stakeholders to monitor PMD's patented testing methodologies and compliance solutions. Bookmark this page for streamlined access to verified updates about workplace safety initiatives and forensic science breakthroughs that define the company's market position.
Psychemedics (NASDAQ: PMD), a leading entity in hair testing for drugs, has launched its inaugural Insights Report. This comprehensive report analyzes drug trends in the workplace, derived from hundreds of thousands of hair samples collected in 2023. The report reveals an overall positive drug test rate of 9.5%, with a 23% increase in positive rates over the last five years. Marijuana, cocaine, and opiates are the most detected substances, while fentanyl shows a troubling rise. The report underscores the effectiveness of hair testing for employment drug screening and aims to help employers and policymakers address workplace drug use. More details can be accessed at the provided link.
Psychemedics (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, announced its Q1 2024 financial results on May 14, 2024. For the quarter ended March 31, 2024, the company reported a revenue of $5.4 million, down 9% from $5.9 million in the same quarter of the previous year. The net loss for Q1 2024 was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $0.07 per share, in Q1 2023. Despite the decline, CEO Brian Hullinger expressed optimism about future growth and revenue stabilization, highlighting the company's ongoing efforts to explore new markets and applications for its hair testing solutions.
FAQ
What is the current stock price of Psychemedics (PMD)?
What is the market cap of Psychemedics (PMD)?
